France Halitosis Treatment Market

ID: MRFR/HC/54791-HCR
200 Pages
Satyendra Maurya
Last Updated: February 06, 2026
France Halitosis Treatment Market Research Report By Indication (Respiratory, Liver, Kidney, Gastrointestinal, Systemic, Others), By Diagnostic Tests (Halimeter, Gas Chromatography, BANA Test, -Galactosidase Activity Assay, Others) and By Drug Treatment (Antacids, Antiseptics, Ranitidine, Others) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

France Halitosis Treatment Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)11.59%
2024 Market Size$ 122.25 Million
2025 Market Size$ 136.42 Million
2035 Market Size$ 408.44 Million

Key Players

Procter & Gamble
Colgate-Palmolive
Unilever
Johnson & Johnson
GlaxoSmithKline
Henkel
Opportunities
  • Rising Health Consciousness
  • Aging Population and Oral Health Issues
  • Influence of Social Media and Marketing
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Indication (USD Million)
      1. 4.1.1 Respiratory
      2. 4.1.2 Liver
      3. 4.1.3 Kidney
      4. 4.1.4 Gastrointestinal
      5. 4.1.5 Systemic
      6. 4.1.6 Others
    2. 4.2 Healthcare, BY Diagnostic Tests (USD Million)
      1. 4.2.1 Halimeter
      2. 4.2.2 Gas Chromatography
      3. 4.2.3 BANA Test
      4. 4.2.4 Β-Galactosidase Activity Assay
      5. 4.2.5 Others
    3. 4.3 Healthcare, BY Drug Treatment (USD Million)
      1. 4.3.1 Antacids
      2. 4.3.2 Antiseptics
      3. 4.3.3 Ranitidine
      4. 4.3.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Procter & Gamble (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Colgate-Palmolive (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Unilever (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Johnson & Johnson (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 GlaxoSmithKline (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Henkel (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Church & Dwight (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Kao Corporation (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY INDICATION
    3. 6.3 FRANCE MARKET ANALYSIS BY DIAGNOSTIC TESTS
    4. 6.4 FRANCE MARKET ANALYSIS BY DRUG TREATMENT
    5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF HEALTHCARE
    8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
    11. 6.11 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    12. 6.12 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
    13. 6.13 HEALTHCARE, BY DIAGNOSTIC TESTS, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY DIAGNOSTIC TESTS, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY DRUG TREATMENT, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY DRUG TREATMENT, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY INDICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSTIC TESTS, 2025-2035 (USD Million)
      3. 7.2.3 BY DRUG TREATMENT, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France France Halitosis Treatment Market Segmentation

France Halitosis Treatment Market By Indication (USD Million, 2025-2035)

  • Respiratory
  • Liver
  • Kidney
  • Gastrointestinal
  • Systemic
  • Others

France Halitosis Treatment Market By Diagnostic Tests (USD Million, 2025-2035)

  • Halimeter
  • Gas Chromatography
  • BANA Test
  • Β-Galactosidase Activity Assay
  • Others

France Halitosis Treatment Market By Drug Treatment (USD Million, 2025-2035)

  • Antacids
  • Antiseptics
  • Ranitidine
  • Others